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The epithelium of the cervix uteri has been reported to be frequently coinfected with both human papillomaviruses (HPV)
and helper virus-dependent adenoassociated viruses (AAV). Seroepidemiological data suggest that AAV infection could
inhibit cervical cancer that is caused by specific (“high-risk”) types of papillomaviruses. In vitro, infection with AAV type 2
(AAV-2) or transfection of AAV-2 early (rep) genes has been shown to inhibit transformation by papillomaviruses. To analyze
the effects of AAV on HPV in vivo, we studied the influence of AAV-2 infection on the promoter activity of high-risk HPV type
18 (HPV-18) in mice, transgenic for sequences of the upstream regulatory region (URR) of HPV-18 controlling transcription
of the reporter gene, lacZ. Transgenic animals (or tongue cells thereof, explanted and grown in culture) were treated with
dexamethasone to induce the HPV-18 promoter. Simultaneously they were (i) infected with AAV, (ii) inoculated with AAV
virus-like particles (VLPs; empty capsids), or (iii) mock infected. Inoculation with AAV-2 or VLPs inhibited activation of the
HPV-18 promoter. In vitro, in baby hamster kidney cells transfected with the HPV-18-lacZ construct, tissue extracts from
AAV-infected animals suppressed the HPV-18 URR to a similar extent as AAV infection did. Down-regulation of the HPV-18
promoter was less efficient with extracts from animals inoculated with VLPs and was not observed with extracts from
uninfected or dexamethasone-treated animals. This indicates that AAV induces cellular factor(s) in vivo capable of mediating
down-regulation of the HPV-18 promoter also in cells in vitro. In contrast, promoters of the low-risk HPV types (HPV-6,
HPV-11) were not influenced by AAV infection as opposed to promoters of the high-risk types (HPV-18 and HPV-16). © 2002
Elsevier Science (USA)INTRODUCTION
Human papillomaviruses (HPV) induce a variety of
proliferative epithelial lesions (papillomas) (for reviews,
see Buckley, 1994; von Knebel Doeberitz, 1992). Certain
HPV types specifically infect the mucosal epithelium of
the anogenital region and a subset thereof (notably types
16 and 18) is causatively linked to genital cancer (Bosch
et al., 1995; Matsukura and Sugase, 1995; zur Hausen,
1999).
The noncoding, upstream regulatory region (URR; 1
kb) of the circular HPV genome is located between the
“late” (L) and the “early” (E) region. The URR contains
control signals for transcription and genome replication,
an epithelial cell-specific enhancer, binding sites for
transcription factors such as AP-1, OCT-1, SP-1, and for
glucocorticoid receptor complexes (Gloss et al., 1987;
Hoppe-Seyler and Butz, 1992; Hoppe-Seyler et al., 1991;
Stanley, 1994; Stra¨hle et al., 1987; Thierry et al., 1992). The
glucocorticoid responsive elements of the URR play an
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been demonstrated in experimental, epidemiological,
and clinical studies (Mittal et al., 1993).
The helper virus dependent human adenoassociated
virus (AAV, six serotypes), a member of the family of
Parvoviridae, is thought to be nonpathogenic and has
tumor suppressive properties (Berns and Giraud, 1996;
Schlehofer, 1994; Schlehofer and Dupressoir, 2000). AAV
seems to establish persistent infection in the human
genital tract (Burguete et al., 1999; Han et al., 1996;
Tobiasch et al., 1994; Walz et al., 1998; Venturoli et al.,
2001), notably in cells of the uterine cervix that is also a
target for latent infections with HPV (cf., de Sanjose et al.,
1999; von Knebel Doeberitz, 1992; zur Hausen, 1994,
1999). It has been demonstrated that AAV inhibits bovine
papillomavirus (BPV)- and HPV-induced transformation in
cell culture (Hermonat, 1994). This inhibition was medi-
ated by the AAV rep gene product (Rep-78) suppressing
the papillomavirus promoter (Hermonat, 1989; Hermonat
et al., 1997; Zhan et al., 1999). In addition, cotransfection
of DNA of HPV type 16 and AAV type 2 (AAV-2) in human
keratinocytes induced a cytopathic effect (Walz et al.,
1997). Furthermore, seroepidemiological data has been
reported demonstrating that women with HPV-relatedKey Words: AAV; HPV; AAV-induced factor; transgene; H
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cervical carcinoma less frequently have antibodies toPV pro172
AAV when compared to age-matched control women
(Georg-Fries et al., 1984; Mayor et al., 1976; Smith et al.,
2001; Sprecher-Goldberger et al., 1971). These data point
to an interaction of AAV and HPV in cervical tissue
possibly interfering with HPV-associated tumor develop-
ment (Rabreau and Schlehofer, 1995; Walz et al., 1997).
To assess interaction of AAV and HPV in vivo, we
investigated the influence of AAV infection on the URR of
HPV-18 in transgenic mice (Cid et al., 1993). In addition,
the effect of tissue extracts from AAV-infected mice on
the HPV-18 promoter was tested in vitro. Furthermore, we
analyzed the influence of AAV on the URR of other HPV
types in vitro. The data demonstrate that AAV inhibits
promoter activity of the high-risk HPV types (HPV-16/18)
in vivo and in vitro (but not of the benign HPV types 6/11)
and that this inhibition is due to AAV-induced cellular
factor(s) in vivo.
RESULTS
AAV down-regulates the HPV-18 promoter in vivo
To examine the influence of AAV on the HPV-18 pro-
moter activity in vivo, we performed experiments with
mice, transgenic for the HPV-18 upstream regulatory
region controlling transcription of the Escherichia coli
-galactosidase reporter gene (HPV-18-URR-lacZ). It had
been shown previously that after treatment with dexa-
methasone, these mice express high levels of -galac-
tosidase in the tongue (Cid et al., 1993). We used this
system of dexamethasone-induced HPV promoter acti-
vation throughout the experiments.
Dexamethasone-treated (supplemented with drinking
water) or untreated animals were intravenously infected
either with infectious AAV-2 (1010–1011 particles per ani-
mal) or with an inoculum of AAV-2 VLPs (1010–1011 parti-
cles per animal). Since dexamethasone-induced URR
activity is maximal after 12 h of treatment, mice were
sacrificed 12 h after infection/treatment, and -galacto-
sidase activity was measured in protein extracts from
tongue tissue of the animals by spectrophotochemical
analysis. As shown in Fig. 1, -galactosidase activity in
tongue tissue was about fivefold higher in animals
treated with dexamethasone, demonstrating URR tran-
scriptional activity mediated by the dexamethasone-in-
ducible glucocorticoid receptor complex, as previously
shown for these mice (Cid et al., 1993; Michelin et al.,
1997). In AAV-2-infected mice, however, this -galactosi-
dase activity was not observed, indicating suppression
of the basal activity as well as of the dexamethasone-
induced HPV-18 promoter activity (Fig. 1A). Similarly,
tongue extracts from animals inoculated with virus-like
particles (VLPs) showed an inhibition of inducible -ga-
lactosidase activity, albeit to a lesser extent than the
effect of infectious virions. Controls, i.e., tongue extracts
from nontransgenic animals or from animals that were
not treated with dexamethasone, exhibited a low back-
ground -galactosidase activity or none at all, respec-
tively (Fig. 1A).
Southern blot analysis of tongues of infected animals
gave no indication of AAV DNA replication or integration
in the cellular genome, as expected after a 12-h infection
(Fig. 1B). In addition to the tongue, genomic AAV DNA
could be also detected by Southern blot analysis in
various tissues of AAV-infected mice (blood, spleen, liver,
kidney, heart, lung, gut, stomach), but not in brain tissue
FIG. 1. (A) -galactosidase activity (units per mg protein) in the
tongue of HPV-18 URR lacZ transgenic mice. As negative controls,
transgene-negative littermates were used. Each group of animals con-
sisted of six male individuals. Expression from the URR in transgenic
animals, treated with dexamethasone [(a) fivefold increased -galac-
tosidase activity above basal activity (b)]. Nontransgenic control ani-
mals did not show any difference of expression treated (e) or not
treated (f) with dexamethasone. In animals treated with dexametha-
sone and infected with AAV-2 showed a nearly complete suppression
of the basal and induced -galactosidase activity (d). Inoculation of
AAV VLPs into transgenic animals down-regulated the dexamethasone-
induced -galactosidase activity (c) less efficiently than infection with
AAV virions (d). (B) Southern blot of genomic DNA (20 g/lane) ex-
tracted from tongues of HPV18-URR lacZ transgenic mice, hybridized
with a radioactively labeled AAV DNA probe. All animals were treated
with dexamethasone. Lanes 1–4: mock-infected control animals; lanes
5–9: animals inoculated intravenously with AAV VLPs; lanes 10–14:
animals infected intravenously with AAV-2 demonstrating AAV in tongue
cells. The 4.6-kb band shows ds AAV DNA, the absence of bands of
higher molecular weight (replicative intermediates) is indicative of lack
of replication of AAV DNA. For each group, four animals were analyzed.
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[data not shown; cf. also earlier results with AAV-infected
nude mice (Walz et al., 1992)].
AAV down-regulates the HPV-18 promoter in vitro
To further assess the influence of AAV on the HPV-18
URR, tongue cells from transgenic mice were isolated
and cultured in vitro. Similar to the observations in vivo,
-galactosidase activity controlled by the HPV-18 URR
was induced after dexamethasone treatment of the cul-
ture (Fig. 2), albeit not in all cells. [This was expected
because of heterogeneity of the cells and since the
transgene is usually not expressed in all cells (Cid et al.,
1993)]. Induction of -galactosidase activity was abol-
ished when tongue cells were infected with AAV (m.o.i.
103 IU/cell) (Fig. 2), or inoculated with VLPs, in which
case inhibition was less pronounced (data not shown).
AAV induces cellular factor(s) in vivo substituting for
AAV in down-regulation of HPV-18 promoter in vitro
It is difficult to conceive that AAV or VLPs reach the
majority of cells of the intravenously injected animals at
the particle number used in the experiments. In addition,
FIG. 2. Inhibition of -galactosidase activity in cells cultured from tongue tissue of HPV-18-URR-LacZ transgenic animals. Cells were treated with
dexamethasone at a concentration of 4 g/ml medium. Cells expressing the transgene from the HPV-18 URR) appear dark stained. (A) Uninfected,
(B) AAV-2-infected (m.o.i.  103 IU/cell) cells.
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without a helper virus, AAV is unlikely to replicate or
express viral genes. Therefore we analyzed whether the
observed strong inhibition of URR activity might be me-
diated by a factor induced in AAV-treated animals. To
address this issue, extracts were prepared from tongue
tissue from transgenic mice that had been (i) infected
with AAV, (ii) inoculated with AAV empty capsids, or (iii)
had not been treated with virus. Experiments were car-
ried out in dexamethasone-treated as well as in un-
treated mice. Extracts were controlled to be free of in-
fectious virions and of AAV DNA.
Extracts were added to BHK cells that had been trans-
fected with HPV-18-URR-lacZ, and the cells were treated
with dexamethasone for 12–16 h to activate the HPV-18
URR. Extracts from tissue from AAV-infected animals
strongly suppressed the URR activity similar to the effect
observed after AAV infection of the cells (Fig. 3). Extracts
from animals inoculated with empty AAV capsids re-
duced -galactosidase expression in the transfected
BHK cells at a lower efficiency (Fig. 3). Similar results
were obtained with extracts from AAV-infected or VLP-
treated BHK cells (but not with cell culture supernatant
from infected cultured cells), suggesting that AAV-medi-
ated induction of cellular factor(s) influencing the HPV-18
URR occurs also in vitro (data not shown). Extracts from
animals treated only with dexamethasone or extracts
from mock-infected animals did not influence the expres-
sion of the transfected reporter gene in the cell cultures.
These data suggest that one or more cellular factors
suppressing the HPV URR are induced in vivo after ex-
posure to AAV-particles.
AAV-mediated down-regulation of the HPV promoter
is restricted to high risk HPV types
To address the specificity of the HPV-18 URR in re-
sponding to AAV, we tested in vitro AAV effects on other
HPV promoters. BHK cells were transfected with con-
structs containing the luciferase gene under the control
of the URR of various HPV types (HPV-18, -16, -6b, -11)
and cultivated with or without dexamethasone. The
transfected cells were either infected with AAV (m.o.i. 
103–104 IU/cell) or transfected with AAV constructs ex-
pressing AAV rep genes. Infection with AAV virions or
expression of AAV rep genes suppressed the URR of
HPV types 16 and 18 induced with dexamethasone (Fig.
4). In these experiments, even the basal activity of the
URR (without induction by dexamethasone) was sup-
pressed. Suppression was more efficient with rep-con-
structs compared to AAV infection, and expression of the
Rep-78 protein exceeded the down-regulating effects of
the expression of all AAV rep genes (Fig. 4). With URR
constructs from the nontumorigenic HPV types 6b and 11,
the dexamethasone-induced activity was much lower
than that observed with HPV-16 and -18, and a significant
reduction of activity was not observed after AAV infection
(Fig. 4).
DISCUSSION
Persistent infection of human genital tissue with AAV
seems to be rather common (Bantel-Schaal and zur
Hausen, 1984; Friedman-Einat et al., 1997; Han et al.,
1996; Tobiasch et al., 1994; Walz et al., 1997, 1998; Ven-
turoli et al., 2001). The same tissue is frequently infected
with HPV (de Sanjose et al., 1999; Gomez et al., 1995; von
Knebel Doeberitz, 1992), certain types thereof (mainly
types 16 and 18) being causatively linked to genital
cancer (zur Hausen, 1994, 1999). Papillomaviruses have
been identified as helpers for AAV replication (Walz et al.,
1997), and an inhibitory effect of AAV functions on tran-
scriptional activity of the transformation-associated HPV
genes, E6/E7, has been reported (Hermonat, 1994; Her-
monat et al., 1997; Zhan et al., 1999). These findings
suggest an interaction of the two viruses in vivo possibly
interfering with HPV-associated tumor development
(Rabreau and Schlehofer, 1995; Walz et al., 1997).
To address this issue we performed experiments with
mice carrying the E. coli lacZ gene under the control of
the promoter region of HPV type 18 as a transgene (Cid
et al., 1993). In these mice, treatment with dexametha-
sone induces expression of -galactosidase by interact-
ing with the glucocorticoid responsive elements of the
HPV-18 upstream regulatory region.
Intravenous injection of AAV-2 and of AAV-2 empty
particles led to suppression of the dexamethasone-in-
duced -galactosidase activity in the HPV-18-URR-lacZ
transgenic animals. This in vivo observation is in line
with previous in vitro results showing down-regulation of
HPV promoter by expression of AAV rep genes (Her-
monat, 1994; Hermonat et al., 1997). It has been shown
that the AAV Rep78 major regulatory protein binds to the
promoter of HPV-16 thereby directly inhibiting E6/E7 tran-
scription (Zhan et al., 1999). However, in the in vivo
system presented here there is no evidence of expres-
sion of AAV Rep proteins after AAV infection, and down-
regulation of the HPV-18 promoter was also observed
with empty AAV particles. Paralleling the in vivo results,
the HPV-18 URR was inhibited in tongue cells from trans-
genic mice explanted in vitro, after infection of the cell
cultures with AAV. In this in vitro assay, treatment with
dexamethasone did not induce -galactosidase expres-
sion in all cells, although all cells contained the trans-
gene. This is in line with earlier studies showing that not
all cells of the transgenic animals can be induced to
express the transgene to the same extent (Cid et al.,
1993).
In in vitro analyses with HPV types other than HPV-18
(HPV-16, HPV-6b, HPV-11), it was observed that down-
regulation by AAV of the HPV URR was restricted to the
“high-risk” types 16 and 18. In BHK cells transfected with
HPV URRs of HPV-16 or -18, controlling the luciferase
reporter gene, not only the dexamethasone-induced URR
activity but also the basal level of the URR was reduced
after infection with AAV. In this system, not only infection
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FIG. 3. In vitro -galactosidase assays. BHK cells, transfected with the HPV-18-URR-lacZ construct were treated as indicated below and cells expressing
the reporter gene were visualized (dark staining cells). All panels are at the samemagnification. (A) Cells treated with dexamethasone; (B) untreated controls;
(C) cells treated with dexamethasone and infected with AAV-2 (m.o.i. 1 103 IU/cell); (D) cells treated with dexamethasone and inoculated with AAV VLPs
(1 103–104 particles/cell); (E) cells treated with dexamethasone and inoculated with protein extract from the tongue of a transgenic mouse that had been
treated with dexamethasone and infected with AAV-2; (F) cells treated with dexamethasone and inoculated with protein extract from the tongue of a
transgenic mouse that had been inoculated with VLPs; (G) untreated cells inoculated with protein extract from the tongue of a control mouse that had been
treated with dexamethasone; (H) cells treated with dexamethasone and inoculated with the same protein extract as in (G).
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with AAV but also expression of AAV rep genes was able
to suppress HPV promoter activity. This indicates that in
addition to effects mediated by AAV virions or empty
particles, AAV Rep proteins down-regulate promoters of
high-risk HPV types, confirming results from others (Her-
monat, 1994).
The results presented here show that infectious viri-
ons as well as empty AAV particles can mediate down-
regulation of HPV-18 URR activity, in vitro and in vivo. As
expected in the absence of AAV helper viruses, there
was no indication of replication of AAV or expression of
AAV proteins. In addition, at least in vivo, it is very
unlikely that a large number of cells are reached by AAV
particles. Therefore we assumed that the observed ef-
fects on HPV URR might be mediated by factors induced
after exposure of cells to AAV particles. This is supported
by our findings that protein extracts from tissue of AAV-
infected animals were able to substitute for AAV infection
in cell-culture experiments. Interestingly, protein extracts
from animals inoculated with VLPs also showed an in-
hibition of expression of the reporter gene, but less
efficiently than extracts from virion-infected animals.
These observations suggest that components of virus
particles interacting with structures or functions of cells
can trigger synthesis of the presumed factor(s). Experi-
ments with extracts from AAV-infected cell cultures indi-
cate that such molecule(s) are also induced in vitro,
albeit less efficiently than tissue extracts from infected
animals.
It cannot be excluded that in experiments with infec-
tious virions a transient expression of Rep proteins might
act directly on the HPV URR (Hermonat et al., 2000; Zhan
et al., 1999), thereby rendering AAV effects more efficient
than the ones observed with empty particles. It remains
to be determined whether the AAV-mediated cellular fac-
tors act directly on the HPV-18 promoter, whether they
interfere with binding of dexamethasone to the glucocor-
ticoid responsive elements of the URR, or whether they
induce cellular functions down-regulating URR activity.
It is tempting to speculate that also in human cervical
tissue, persistent AAV—possibly replicated through the
helper activity of HPV—may down-regulate E6/E7 ex-
pression of oncogenic HPVs. This inhibition of HPV pro-
moters may not only be achieved by direct interaction of
FIG. 4. Suppression of luciferase activity controlled by URRs of different HPV types after exposure to AAV. BHK cells were transfected with HPV
URR constructs controlling luciferase expression, treated or not with dexamethasone (4 g/ml), infected with AAV (m.o.i.  103 IU/cell), or
cotransfected with constructs expressing AAV rep genes. Light columns, luciferase expression in dexamethasone-treated cells, dark columns, without
dexamethasone. w/AAV, AAV-infected; wo/AAV, uninfected cells; w/delta-VP, cotransfection with a construct expressing all AAV-2 rep genes under the
control of the natural AAV promoter; w/rep-78, cotransfection with a construct expressing the Rep 78 protein under the control of the CMV promoter.
(A) HPV-18 URR (2 AAV stocks were tested); (B) HPV-16 URR; (C) HPV-6b URR; (D) HPV-11 URR; (E) HPV-18 URR; (F) HPV-16 URR.
177AAV-MEDIATED HPV-18 PROMOTER INHIBITION IN VIVO
early AAV proteins with the HPV promoter but also via
AAV-induced cellular factors acting on the activity of the
HPV URR. Such AAV-mediated functions might explain
epidemiological observations, indicating a somewhat
protective effect of AAV on development of HPV-associ-
ated cervical cancer (Georg-Fries et al., 1984; Mayor,
1993; Mayor et al., 1976; Sprecher-Goldberger et al.,
1971; Smith et al., 2001).
AAV infection and empty AAV particles have been
shown to sensitize a variety of human tumor cells to
irradiation or to the cytotoxic action of chemotherapeutic
drugs, in vitro and also in vivo (i.e., tumors derived from
human tumor cells inoculated in nude mice) (Hillgenberg
et al., 1999; Klein-Bauernschmitt et al., 1996; Walz et al.,
1992). It is unexplained how a relatively low dose of
viruses injected into animals achieved this sensitizing
effect on the relatively big tumor mass. The finding of
AAV-mediated induction of cellular factors presented
here might hint to such factors also involved in rendering
tumor cells more sensitive to genotoxic agents.
The present study focused on in vivo effects of AAV
infection on HPV promoter activity. Future experiments
are required to identify and characterize the molecular
nature of AAV-induced cellular factor(s). Recently, a cy-
tokine-like peptide (AiF, AAV-induced factor) has been
described that is secreted from melanoma cell cultures
after integration of AAV-2 DNA (Bantel-Schaal, 2001). This
factor is described to influence cell adhesion and to
modulate cell proliferation in opposite ways for tumor
cells and fibroblasts. Though this factor seems to be
induced upon integration of AAV DNA and has not yet
been connected to papillomaviruses, it will be interesting
to compare it with the factor(s) induced in the experi-
ments described in this report.
MATERIAL AND METHODS
Animals
A homogeneous colony of male mice, heterozygous
for the transgene, E. coli -galactosidase gene, under
the control of the HPV-18 upstream regulatory region,
URR (pURR-18-lacZ) (Cid et al., 1993), was used for in vivo
experiments. The animals were conceived by injection of
transgene-positive pronuclei of eggs of C57/BL6xC3H
hybrids. The strongest expression of the reporter gene
was found in the tongue, gonads, uterus, stomach, small
intestine, kidney, hair follicles, and respiratory epithelium
(Cid et al., 1993). Heterozygous animals were crossbred
to obtain homozygous breeder animals. (Animals were
kept under conditions approved by the Loyola University
of Chicago Medical Center Institutional Animal Care and
Use Committee and the German Tierschutzgesetz.) The
status of the transgene was analyzed by PCR (see be-
low). To distinguish homozygous from heterozygous
(PCR-positive) individuals, animals were crossbred with
transgene-negative littermates. After obtaining homozy-
gous animals, these were bred with negative littermates
to obtain hemizygous male animals for the assays. For
identification of mice carrying the transgene, DNA from
tail biopsies was analyzed by PCR utilizing the following
HPV-18 URR-specific primers (Cid et al., 1993; Michelin et
al., 1997): 5-TAC AAG CCA AGT ATG CAA TTA GC-3;
5-TAC GTG CCA GGA AGT AAT ATG TG-3. Amplification
was performed using a PTC-100 thermocycler (MJ Re-
search Inc., Watertown, MA) with 1 cycle at 95°C for 5
min followed by 30 cycles of 40 s at 94°C; 40 s at 63°C,
and 30 s at 75°C; and a final cycle at 75°C for 5 min. As
a positive PCR control, 20 g genomic DNA from HPV-18
DNA-positive HeLa cells was used. PCR products were
separated by electrophoresis through a 1% agarose gel
containing ethidium bromide. The products were visual-
ized under UV light and photographed.
Cells
Baby hamster kidney cells (BHK) and 293 cells were
grown at 37°C and 5% CO2 in Dulbecco’s modified Ea-
gle’s medium (DMEM) with antibiotics (10 g/ml penicil-
lin and 20 g/ml streptomycin) and 10% fetal calf serum.
Cells from mouse tongue from URR-18-LacZ trans-
genic mice were isolated and propagated as follows.
Mice were sacrificed by cervical dislocation and the
tongue was removed and carefully cut into small pieces
with a sterile scalpel in sterile medium (4 ml DMEM,
supplemented with 20% FCS and antibiotic–antimycotic
solution, Gibco-BRL, Grand Island, NY) in a 10-cm culture
dish. Medium containing the fragments was transferred
into a 50-ml Falcon tube and 1 ml HEPES buffer (pH 7.0),
250 l collagenase IV (stock, 60 mg/ml, Sigma, Deisen-
hofen, Germany), 250 l DNase I (stock, 25 mg/ml,
Boehringer, Mannheim, Germany) and 400 l hyaluroni-
dase (stock, 10 mg/ml, Sigma) were added. Cells of the
tissue were separated with constant shaking for at least
4 h at 37°C. Finally the digested tongue cells were
suspended by repeated pipetting and transferred into
six-well plates and incubated with medium (as above).
Medium was changed after 8 and 16 h.
Virus
AAV-2 was propagated in HeLa cells with adenovirus
type 2 (ATCC, Rockville, MD) as the helper and purified
as described (Yakobson et al., 1987). Infectious particles
were analyzed by end-point titration (Bantel-Schaal and
zur Hausen, 1988) and by a capsid-specific ELISA to
determine the number of physical particles (Grimm et al.,
1999). The “mock” inoculum was a dialyzed fraction (1.41
g/cm3) from a CsCl gradient from HeLa cells only in-
fected with adenovirus type 2.
Empty AAV-2 particles (“Virus-like particles”)
293 cells were infected with recombinant adenovirus
expressing AAV VP genes (Grimm et al., 1999) and main-
tained in culture until complete adenovirus-induced cy-
topathic effect (CPE) appeared. Cells were harvested
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and sedimented by centrifugation (5 min, 200 g, 4°C),
and VLPs were purified as described by Wistuba et al.
(1997). The number of empty particles was adjusted to
the one of physical particles present in the preparation of
infectious AAV, as determined by the capsid ELISA
(Grimm et al., 1999) and by estimating protein content in
Western blot analyses with anticapsid antibodies recog-
nizing only entire particles. This allowed similar numbers
of input particles in experiments with infectious and
empty particles.
Plasmids
The following plasmids were used for transfection in
BHK cells. p-URR-18-lacZ [whole URR from HPV-18 as
1050-bp fragment cloned in front of the E. coli -galac-
tosidase gene in the plasmid pC4AUG--gal (Cid et al.,
1993)]; pURR-18-LUC (whole URR from pURR-18-lacZ
subcloned into the firefly luciferase expression vector
pBL into the BamHI/PstI site); pURR-16-LUC (whole URR
from HPV-16 cloned into pBL into the BamHI/PstI site);
pURR-6b-LUC (whole URR from HPV-6b cloned into the
BamHI/PstI site of pBL); pURR-11-LUC (whole URR from
HPV-11 cloned into the BamHI/PstI site of pBL); pTK-RL
[cDNA of Renilla luciferase cloned behind the TK-promot-
er-enhancer as described by manufacturer (Promega,
Madison, WI)]; pTK-LUC [positive control for the Firefly
luciferase cloned behind the TK-promoter-enhancer (Pro-
mega)]; pAAV--VP (AAV genome without VP genes, ex-
pressing the nonstructural rep genes from their own
promoters p5 and p19); pCMV-rep78 (AAV rep 78 gene
cloned behind the early CMV promoter).
With these plasmids, 80% confluent growing cells
were transfected or cotransfected with different HPV-
URR-LUC constructs, the internal control pTK-RL, and
constructs from AAV described above. Two micrograms
of DNA were transfected with LipofectAMINE (Life Tech-
nologies, Eggenstein, Germany) in 2  105 cells accord-
ing to the manufacturer’s recommendations. Control ex-
periments using the pBluescript plasmid instead of the
internal control pTK-RL excluded specific effects of the
pTK-RL.
In vivo infection/treatment
Transgenic animals as well as nontransgenic litter-
mates were infected with purified AAV-2 or VLPs by
injection into the tail vein (1010–1011 infectious units per
animal). To induce strong expression of the reporter
gene from the HPV promoter in the transgenics, dexa-
methasone was administered at the time of AAV infection
by addition to the drinking water [4 g/ml (105 M) from
a 10 mg/ml stock of crystalline hormone (Sigma-Aldrich,
Deisenhofen, Germany) in ethanol]. Control animals
were either mock-infected or did not receive dexameth-
asone. Nontransgenic littermates were negative controls
receiving the same treatment as the transgenics. The
animals were sacrificed by cervical dislocation, 12 h after
onset of treatment and infection.
Southern blot analysis
DNA was extracted from tissue samples of spleen,
liver, lung, kidney, heart, gut, stomach, tongue, blood, and
brain of infected or mock-infected animals (12 h p.i.)
using standard procedures. Twenty micrograms of each
DNA sample was digested with EcoRV (not cutting within
the AAV DNA genome), separated on a 0.7% agarose gel,
and transferred onto Nylon membranes. Blots were hy-
bridized with genomic AAV DNA [pTAV2; (Heilbronn et al.,
1990)] and autoradiographed.
In vivo -galactosidase assay
The -galactosidase activity in the tongue tissue of the
animals was determined with the ONPG (o-nitrophenol-
-D-galactopyranoside) assay. Tongues from sacrificed
animals were cut into small pieces using a sterile scal-
pel. The tissue fragments were transferred into PM2
buffer [33 mM NaH2PO4, 66 mM Na2HPO4, 0.1 mM
MnCl2, 2 mM MgSO4, 40 mM -mercaptoethanol (pH,
7.3)] and homogenized on ice with a polytron homoge-
nizer. Tissue homogenates were centrifuged and resus-
pended three times at 12,000 g for 15 min at 4°C. The
supernatant was transferred into a microcentrifuge tube
and protein concentration was determined as described
(Bradford, 1976). Protein (300 g) and ONPG (800 g)
were transferred into a final volume of 1 ml PM2 buffer at
37°C. Immediately after adding ONPG, the initial absorp-
tion (A420) of each sample was read. Readings were
taken every 30–60 min over a time of incubation at (37°C)
of up to 10 h. The -galactosidase activity was calculated
after subtraction of the individual initial values: units 
[380 A 420/time (in minutes) 3,3333; 380 is a constant,
so that 1 unit is equivalent to the conversion of 1 nM
ONPG per minute at 37°C]. Since 300 g protein extract
was in the reaction, the final unit value for 1 mg protein
was calculated by multiplying with 3.3333.
In vitro infection/treatment
Primary cells prepared from the tongue of transgenic
animals, or BHK cells (80% confluent), were transfected
with the various HPV plasmid constructs. They were then
inoculated with AAV-2 (m.o.i.  103–104 IU/cell), or with
VLPs (adjusted for the number of particles, see above)
and incubated with medium containing dexamethasone
(final concentration, 4 g/ml) at 37°C for 12–16 h prior to
analyses of HPV promoter activity (see below). As con-
trols, cells treated only with dexamethasone or untreated
cells were used.
In vitro -galactosidase assay
Explanted tongue cells (transgenic for HPV18-URR-
lacZ) or BHK cells (transfected with the HPV-18-URR-
179AAV-MEDIATED HPV-18 PROMOTER INHIBITION IN VIVO
LacZ plasmid) were washed twice with PBS and fixed
with 3% formaldehyde in PBS (pH 7.5) at 4°C for 20 min.
Fixed samples were washed with PBS at RT and incu-
bated with X-gal reaction solution [1 mg/ml X-gal, 5 mM
K3Fe(CN)6 and 5 mM K4Fe(CN)6 in 2 mM MgCl2 0.02%
Nonidet P-40 (NP-40) 0.01% Na deoxycholate in 0.1 M
phosphate buffer (66 mM Na2HPO4, 33 mM NaH2PO4; pH
7.3)] for 1–12 h at 37°C in a humidified atmosphere. The
number of cells staining blue was determined micro-
scopically.
Incubation of cells with extracts from tongue tissue
of mice
Proteins were extracted from tongue tissue of AAV- or
VLP-infected and control mice as described above. Pro-
tein extracts were treated with DNase to remove poten-
tial AAV DNA sequences. In addition, 5 l of DNase-
treated extract was inoculated in HeLa cells infected
with adenovirus, demonstrating the absence of infec-
tious virus. Similar extracts were prepared from AAV-
infected BHK cells. After complete adenovirus-induced
CPE, cells were transferred onto a nylon membrane and
lysed as described (Walz et al., 1997). The lysed cells
were hybridized with radioactively labeled AAV DNA to
detect replication of AAV. Virus-free protein extract (100
g diluted in 5-ml full medium) was added to BHK cell
cultures (80% confluent, treated or not with dexametha-
sone) that had been transfected 12–16 h before with the
URR-18-lacZ reporter plasmid. After 16 h, in vitro -ga-
lactosidase assay was performed (see above) and the
number of blue cells was determined microscopically.
In vitro luciferase assay
BHK cells transfected with luciferase constructs of
various HPV types (see above) were either infected with
AAV (m.o.i.  103–104 IU/cell) or transfected with AAV
constructs (see above). Cultures were incubated over-
night in medium containing dexamethasone or not, as
described in the figures. After lysis of the cells, the firefly
luciferase activity in the cell extracts was measured
against the internal control of the renilla luciferase in a
luminometer using the Dual-Luciferase Reporter 1000
Assay System from Promega (Madison, WI).
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